Skip to main content

Table 3 Median TTP, HR and 95%CIs between combination therapy group and TACE alone group

From: Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Authors (year)

Combination group (95% CI)/months

TACE alone group (95% CI)/months

HR (95% CI)

Kudo et al. (2011) [15]

5.4(3.8–7.2)

3.7 (3.5–4.0)

0.87(0.70–1.09)

Sansonno et al.(2012) [44]

9.2

4.9

2.5(1.66–7.56)

Lencioni et al. (2012) [10]

5.6

5.5

0.797 (0.588–1.08)

Bai et al. (2013) [46]

6.3

4.3

0.6 (0.422–0.853)

Muhammad et al. (2013) [47]

NA

NA

0.93 (0.45–1.89)

Huang et al. (2013) [48]

5.4

3.7

0.99 (0.67–1.47)

Hu et al. (2014) [14]

2.6

1.9

0.62 (0.47–0.82)

Ohki et al. (2015) [6]

6.3

3.5

0.38 (0.22–0.63)

Yao et al. (2015) [12]

10.2

6.7

0.403 (0.251–0.646)

Zhang et al. (2016) [49]

4.9 (3.7–6.0)

2.4 (1.3–3.4)

NA

  1. Abbreviations: TTP time to progression, HR hazard ratio, 95%CIs 95% confidence intervals, NA not available